Matt Birney

Burleson Energy have easily raised $4.5m to complete the acquisition of Israeli nano-satellite company Sky and Space Global. The company announced this week Danish nano-satellite manufacturer Gom Space, has commenced construction of SSG’s first three nano-satellites.

In a supreme show of faith in ASX listed Analytica’s urinary incontinence medical device technology, its Chairman Dr Michael Monsour has agreed to take a $1m placement at a price nearly 18 percent higher than that offered to the general shareholder base and a new cornerstone investor who has also committed to a $500k placement. 

A major part of Stargroup’s plan is about to come to fruition with the appointment of 20 agents nationwide who will resell their EFTPOS and PAYWAVE offering to businesses around the country.They are aiming to place 30 EFTPOS terminals a month into businesses up until July and 100 a month thereafter as their network of agents grows to over 100 by midyear. 

Burleson Energy acquisition Sky and Space Global have pre-sold 100% of the telecommunications bandwidth from their first constellation of “nano-satellites” to be launched in 2017. The company says that just 100 units should provide revenues of between $300m and $500m per annum and produce up to 1 000 000 000  minutes of voice, messaging and data air time a year.

Hammer Resources and heavyweight partner Newmont are currently processing and modelling geophysical data gleaned from the first round of field programs at Hammer’s Mt Isa project. Hammer are also focusing on their own 100% owned tenements including the Scalper prospect that retunred a result of 23 metres at 1.1% Copper and 0.27g/t gold.

West Perth based Drake Resources has made the popular leap from mining to technology with the acquisition of Israeli based cyber security firm Genome Technologies that boasts a unique proprietary algorithm that “profiles” client company employees in order to assess their cyber security risk. The deal is worth around $11m and Drake says the cyber security market will grow to $177b in 5 years.

Leading ASX listed Cancer drug specialist Pharmaust, are in discussions with a UK-based clinical oncologist to evaluate their anti-cancer drug known as Monepantel in patients with oesophageal cancer. The trials, which will analyse the effect of Monepantel on patient’s tumours are designed to provide short term feedback on the efficacy of the drug.

Despite encountering drilling difficulties that resulted in the abandonment of two holes at their Rockford project in the Fraser Range, Legend Mining says it gained a valuable insight into the geology in the area. Legend says it is able to confirm the presence of “Fraser Zone” rocks highlighting the prospectively of Area D for Nickel and Copper mineralisation.

Consummate deal maker Neometals is at it again, this time with ASX listed junior and 20% partner in its WA nickel assets, Hannans Reward. In a complex series of deals, Neometals will divest its nickel assets in Forrestonia , whilst at the same time emerging as Hannan’s major shareholder with around 40% of its shares and a 13.5% stake in an overseas Lithium play.